IRWD Ironwood Pharmaceuticals Inc

USD 8.62 0.30 3.605769
Icon

Ironwood Pharmaceuticals Inc (IRWD) Stock Analysis and Price Targets

COMMON STOCK | Drug Manufacturers - Specialty & Generic | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 8.62

+0.30 (+3.61)%

USD 1.36B

3.28M

USD 19.67(+128.15%)

N/A

Icon

IRWD

Ironwood Pharmaceuticals Inc (USD)
COMMON STOCK | NSD
USD 8.62
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 1.36B

N/A

USD 8.62

Ironwood Pharmaceuticals Inc (IRWD) Stock Forecast

USD 19.67
(+128.15%)

Based on the Ironwood Pharmaceuticals Inc stock forecast from 5 analysts, the average analyst target price for Ironwood Pharmaceuticals Inc is USD 19.67 over the next 12 months. Ironwood Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Ironwood Pharmaceuticals Inc is Slightly Bullish , which is based on 6 positive signals and 5 negative signals. At the last closing, Ironwood Pharmaceuticals Inc’s stock price was USD 8.62. Ironwood Pharmaceuticals Inc’s stock price has changed by -5.38% over the past week, -43.21% over the past month and -20.33% over the last year.

No recent analyst target price found for Ironwood Pharmaceuticals Inc
No recent average analyst rating found for Ironwood Pharmaceuticals Inc

Company Overview Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with con...Read More

100 Summer Street, Boston, MA, United States, 02110

267

December

USD

USA

Adjusted Closing Price for Ironwood Pharmaceuticals Inc (IRWD)

Loading...

Unadjusted Closing Price for Ironwood Pharmaceuticals Inc (IRWD)

Loading...

Share Trading Volume for Ironwood Pharmaceuticals Inc Shares

Loading...

Compare Performance of Ironwood Pharmaceuticals Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for IRWD

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Ironwood Pharmaceuticals Inc (Sector: Drug Manufacturers - Specialty & Generic )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ZTS
Zoetis Inc +2.84 (+1.71%) USD79.01B 34.04 22.84

ETFs Containing IRWD

Symbol Name IRWD's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Ironwood Pharmaceuticals Inc (IRWD) Stock

Based on ratings from 5 analysts Ironwood Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 6 buy, sell and hold ratings.

Unfortunately we do not have enough data on IRWD's stock to indicate if its a good dividend stock.

Based on targets from 5 analysts, the average taret price for IRWD is USD 19.67 over the next 12 months. The maximum analyst target price is USD 22 while the minimum anlayst target price is USD 14.

IRWD stock's Price/Earning ratio is 9.67. Our analysis grades IRWD stock's Price / Earning ratio at D-. This means that IRWD stock's Price/Earning ratio is above 39% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange. Based on this IRWD may be fairly valued for its sector

The last closing price of IRWD's stock was USD 8.62.

The most recent market capitalization for IRWD is USD 1.36B.

Based on targets from 5 analysts, the average taret price for IRWD is projected at USD 19.67 over the next 12 months. This means that IRWD's stock price may go up by +128.15% over the next 12 months.

We can't find any ETFs which contains Ironwood Pharmaceuticals Inc's stock.

As per our most recent records Ironwood Pharmaceuticals Inc has 267 Employees.

Ironwood Pharmaceuticals Inc's registered address is 100 Summer Street, Boston, MA, United States, 02110. You can get more information about it from Ironwood Pharmaceuticals Inc's website at https://www.ironwoodpharma.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...